872059-27-3

Usage

Uses

Used in Organic Synthesis:
7-chloro-5-(Methylthio)imidazo[1,2-c]pyrimidine is utilized as a key intermediate in organic synthesis for the preparation of a variety of pharmaceutical compounds and agrochemicals. Its unique structure allows for the creation of diverse chemical entities with potential applications in different fields.
Used in Drug Discovery Research:
In the pharmaceutical industry, 7-chloro-5-(Methylthio)imidazo[1,2-c]pyrimidine serves as a building block for the development of new drugs and bioactive molecules. Its molecular structure provides a foundation for the design and synthesis of compounds with therapeutic potential, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Development:
Similarly, in the agrochemical sector, 7-chloro-5-(Methylthio)iMidazo[1,2-c]pyriMidine is employed as a precursor in the synthesis of various agrochemicals. Its properties make it suitable for the development of new pesticides, herbicides, or other agricultural chemicals that can enhance crop protection and yield.
Overall, 7-chloro-5-(Methylthio)imidazo[1,2-c]pyrimidine is a versatile chemical entity with applications spanning across multiple industries, primarily due to its unique molecular structure and the potential for further chemical modification.

Upstream product

• 107-20-0 2-chloroethanal 
• 1005-38-5 4-amino-6-chloro-2-methylthiopyrimidine 
• 6299-25-8 4,6-Dichloro-2-(methylthio)pyrimidine 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 

Downstream Products

• 872059-28-4 5-methylsulfanyl-7-phenyl-imidazo[1,2-c]pyrimidine 
• 56817-09-5 7-chloroimidazo[1,2-c]pyrimidin-5-ol 
• 85989-61-3 5,7-dichloro-imidazo<1,2-c>pyrimidine 

Relevant academic research and scientific papers

Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors

Compound 13 was discovered through morphing of the ATR biochemical HTS hit 1. The ABI series was potent and selective for ATR. Incorporation of a 6-azaindole afforded a marked increase in cellular potency but was associated with poor PK and hERG ion channel inhibition. DMPK experiments established that CYP P450 and AO metabolism in conjunction with Pgp and BCRP efflux were major causative mechanisms for the observed PK. The series also harbored the CYP3A4 TDI liability driven by the presence of both a morpholine and an indole moiety. Incorporation of an adjacent fluorine or nitrogen into the 6-azaindole addressed many of the various medicinal chemistry issues encountered. (Chemical Presented).

SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES

The invention relates to substituted imidazopyrimidines and triazolopyrimidines, to methods for the production thereof, and to the use of same for producing medicaments for the treatment and/or prophylaxis of diseases, especially haematological diseases, preferably leucopenia and neutropenia.

Substituted heterocyclic compounds and methods of use

The present invention relates to triazolopyrimidines, imidazolopyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis,